169 related articles for article (PubMed ID: 38443927)
1. Glioma-targeted oxaliplatin/ferritin clathrate reversing the immunosuppressive microenvironment through hijacking Fe
Li X; Cheng Y; Yang Z; Ji Q; Huan M; Ye W; Liu M; Zhang B; Liu D; Zhou S
J Nanobiotechnology; 2024 Mar; 22(1):93. PubMed ID: 38443927
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin disrupts pathological features of glioma cells and associated macrophages independent of apoptosis induction.
Roberts NB; Alqazzaz A; Hwang JR; Qi X; Keegan AD; Kim AJ; Winkles JA; Woodworth GF
J Neurooncol; 2018 Dec; 140(3):497-507. PubMed ID: 30132163
[TBL] [Abstract][Full Text] [Related]
3. Oroxylin A reversed Fibronectin-induced glioma insensitivity to Temozolomide by suppressing IP
Ding Y; Zhou Y; Li Z; Zhang H; Yang Y; Qin H; Xu Q; Zhao L
Life Sci; 2020 Nov; 260():118411. PubMed ID: 32918978
[TBL] [Abstract][Full Text] [Related]
4. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
[TBL] [Abstract][Full Text] [Related]
5. Nano-Codelivery of Temozolomide and siPD-L1 to Reprogram the Drug-Resistant and Immunosuppressive Microenvironment in Orthotopic Glioblastoma.
Liu D; Cheng Y; Qiao S; Liu M; Ji Q; Zhang BL; Mei QB; Zhou S
ACS Nano; 2022 May; 16(5):7409-7427. PubMed ID: 35549164
[TBL] [Abstract][Full Text] [Related]
6. Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma.
Ding C; Yi X; Chen X; Wu Z; You H; Chen X; Zhang G; Sun Y; Bu X; Wu X; Lin Z; Gu J; Lin Y; Kang D
J Exp Clin Cancer Res; 2021 May; 40(1):164. PubMed ID: 33975615
[TBL] [Abstract][Full Text] [Related]
7. MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway.
Li C; Feng S; Chen L
Mol Cell Biochem; 2021 Feb; 476(2):699-713. PubMed ID: 33106913
[TBL] [Abstract][Full Text] [Related]
8. Exosomal circ-HIPK3 Facilitates Tumor Progression and Temozolomide Resistance by Regulating miR-421/
Han C; Wang S; Wang H; Zhang J
Cancer Biother Radiopharm; 2021 Sep; 36(7):537-548. PubMed ID: 32644821
[No Abstract] [Full Text] [Related]
9. Impact of chemotherapeutic agents on liver microenvironment: oxaliplatin create a pro-metastatic landscape.
Ma Y; Guo C; Wang X; Wei X; Ma J
J Exp Clin Cancer Res; 2023 Sep; 42(1):237. PubMed ID: 37697332
[TBL] [Abstract][Full Text] [Related]
10. LINC01564 Promotes the TMZ Resistance of Glioma Cells by Upregulating NFE2L2 Expression to Inhibit Ferroptosis.
Luo C; Nie C; Zeng Y; Qian K; Li X; Wang X
Mol Neurobiol; 2022 Jun; 59(6):3829-3844. PubMed ID: 35420382
[TBL] [Abstract][Full Text] [Related]
11. CD147 confers temozolomide resistance of glioma cells via the regulation of β-TrCP/Nrf2 pathway.
Bu X; Qu X; Guo K; Meng X; Yang X; Huang Q; Dou W; Feng L; Wei X; Gao J; Sun W; Chao M; Han L; Hu Y; Shen L; Zhang J; Wang L
Int J Biol Sci; 2021; 17(12):3013-3023. PubMed ID: 34421346
[No Abstract] [Full Text] [Related]
12. Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433).
Kumari S; Ahsan SM; Kumar JM; Kondapi AK; Rao NM
Sci Rep; 2017 Jul; 7(1):6602. PubMed ID: 28747713
[TBL] [Abstract][Full Text] [Related]
13. A Fe(III)-porphyrin-oxaliplatin(IV) nanoplatform for enhanced ferroptosis and combined therapy.
Hu X; Li R; Wu W; Fang K; Zhu Z; Wang Y; Zhou L; Chen M; Dong C; Shi S
J Control Release; 2022 Aug; 348():660-671. PubMed ID: 35716884
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-29b promotes cell sensitivity to Temozolomide by targeting STAT3 in glioma.
Xu JX; Yang Y; Zhang X; Luan XP
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):1922-1931. PubMed ID: 32141561
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-302c enhances the chemosensitivity of human glioma cells to temozolomide by suppressing P-gp expression.
Wu Y; Yao Y; Yun Y; Wang M; Zhu R
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31409725
[TBL] [Abstract][Full Text] [Related]
16. MicoRNA-214-3p: a key player in CPLX2-mediated inhibition on temozolomide resistance in glioma.
Peng Q; Wang L; Wang S; Wang C; Xue Z
Neurol Res; 2022 Oct; 44(10):879-887. PubMed ID: 36117461
[TBL] [Abstract][Full Text] [Related]
17. Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
Hu YH; Jiao BH; Wang CY; Wu JL
CNS Neurosci Ther; 2021 May; 27(5):552-563. PubMed ID: 33460245
[TBL] [Abstract][Full Text] [Related]
18. Blockade of Na/H exchanger stimulates glioma tumor immunogenicity and enhances combinatorial TMZ and anti-PD-1 therapy.
Guan X; Hasan MN; Begum G; Kohanbash G; Carney KE; Pigott VM; Persson AI; Castro MG; Jia W; Sun D
Cell Death Dis; 2018 Sep; 9(10):1010. PubMed ID: 30262908
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of circHIPK3 Facilitates Temozolomide Sensitivity in Glioma by Regulating Cellular Behaviors Through miR-524-5p/KIF2A-Mediated PI3K/AKT Pathway.
Yin H; Cui X
Cancer Biother Radiopharm; 2021 Sep; 36(7):556-567. PubMed ID: 32833501
[No Abstract] [Full Text] [Related]
20. NCK1-AS1 Increases Drug Resistance of Glioma Cells to Temozolomide by Modulating miR-137/
Chen M; Cheng Y; Yuan Z; Wang F; Yang L; Zhao H
Cancer Biother Radiopharm; 2020 Mar; 35(2):101-108. PubMed ID: 31750728
[No Abstract] [Full Text] [Related]
[Next] [New Search]
